Jump to content

Fluclotizolam

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Vortioxetine (talk | contribs) at 16:17, 13 December 2020 (Added SVG of structure). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Fluclotizolam
Legal status
Legal status
Identifiers
  • 2-chloro-4-(2-fluorophenyl)-9-methyl-4H-thieno[3,2-f] [1,2,4]triazolo[4,3-a] [1,4]diazepine
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H10ClFN4S
Molar mass332.78 g·mol−1
3D model (JSmol)
  • Fc4ccccc4C2=NCc1nnc(C)n1c3sc(Cl)cc23
  • InChI=1S/C15H10ClFN4S/c1-8-19-20-13-7-18-14(9-4-2-3-5-11(9)17)10-6-12(16)22-15(10)21(8)13/h2-6H,7H2,1H3
  • Key:ZDYRCUZZLRLMHG-UHFFFAOYSA-N

Fluclotizolam is a thienotriazolodiazepine derivative which was first synthesised in 1979,[1] but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified in 2017.[2][3][4]


See also

References

  1. ^ US 4155913, Hellerbach J, Zeller P, Binder D, Hromatka O, "Thienotriazolodiazepine derivatives.", issued 22 May 1979, assigned to Hoffmann La Roche Inc 
  2. ^ Zawilska JB, Wojcieszak J (July 2019). "An expanding world of new psychoactive substances-designer benzodiazepines". Neurotoxicology. 73: 8–16. doi:10.1016/j.neuro.2019.02.015. PMID 30802466.
  3. ^ Moosmann B, Auwärter V (2018). "Designer Benzodiazepines: Another Class of New Psychoactive Substances.". In Maurer H, Brandt S (eds.). New Psychoactive Substances. Handbook of Experimental Pharmacology. Handbook of Experimental Pharmacology. Vol. 252. pp. 383–410. doi:10.1007/164_2018_154. ISBN 978-3-030-10560-0. PMID 30367253.
  4. ^ Chetraru E, Ameline A, Gheddar L, Raul JS, Kintz P (February 2018). "Les designer benzodiazepines: qu'en sait-on aujourd'hui?". Toxicologie Analytique et Clinique. 30 (1): 5–18. doi:10.1016/j.toxac.2017.12.001.